Eisai faces delay for cancer drug

The FDA has delayed Eisai's NDA submission for E7389 (eribulin mesylate) for third-line treatment of advanced breast cancer. The company was hoping to gain accelerated approval for the drug, but can't because Bristol-Myers Squibb won approval for another drug for the same indication last October. The drug is also in Phase II trials for prostate cancer.

- see this release for more

Related Articles:
Eisai expands U.S. ops with $3.9B MGI buyout. Report
Eisai acquires Morphotek in $325M deal. Report
Eisai plans $105M expansion in NC. Report